X-MAN^TM cell lines are genetically-defined isogenic human cell-line pairs that accurately model a target gene in the context of an individual patient genotype enabling you to challenge your lead compounds! These 'patient-relevant' cell-based tools will allow you to quickly define a drug candidate's specific activity and likely patient responsiveness or resistance prior to entering clinical trials using a high-throughput assay. 

X-MAN cell lines are generated using the GENESIS^TM platform - a proprietary technology of Horizon Discovery Limited.

Broad Applications in Drug Discovery

Targeting single defects using the X-MAN Discovery 1 panel of cell lines is the first step into understanding how different patient populations respond to a drug; but it is becoming critical to check if other (secondary) mutations impart resistance. This is a key feature of the X-MAN Discovery 2 panel of cell lines (or double knock-ins).

Discovery 1 X-MAN - Single Mutated Cancer Gene Panel
•  Primary druggable mutant vs. normal human cancer genotypes
•  25+ single KI/KO  cell-lines
•  Target selectivity; target ID, biomarkers, patient-relevance
•  X-MAN Express protein & mRNA lysates

Discovery 2 X-MAN - Double Mutated Cancer Gene Panel
•  Primary druggable mutant vs. normal human cancer genotypes
•  5+ double KI cell-lines
•  Drug resistance/ drug combinations/ repositioning; biomarkers; patient-relevance
•  X-MAN Express protein & mRNA lysates

X-MAN Researcher - Cancer Associated/ Modifier Gene Panel
•  Secondary de-regulated mutant vs. normal human cancer genotypes
•  60+ KO cell-lines
•  Target selectivity; target ID; pathway de-regulation studies
•  X-MAN Express protein & mRNA lysates

X-MAN Express
The X-MAN Express range provides researchers with ready-to-use protein cell-lysates from any of the X-Man cellular models. These lysates can be used directly in a variety of proteomics research applications.
 
CDAS offers a wide range of products and services using X-Man cell lines: 

- Compound Screening and Profiling: Short-cut activity screens, patient selectivity profiling
- Strategic Partnerships: Custom programs combining CDAS oncology service platforms.
- Cell-Line Licensing: For Evaluation, R&D, Screening, Clinical-Trial Design,
- Custom Engineering: Design your own X-Man cancer models



Technology Platform

GENESIS is a proprietary gene-engineeing platform that enables virally-mediated isogenic targeting of any endogenous gene in human cells.

 Using the GENESIS platform, precisely and stably aletred genotypes exhibiting gain-of-function can be constructed in a range of cell-types (including normal cells).

For further information about the GENESIS Technology please visit the Horizon Discovery website or view the Genesis Technology Datasheet.

Isogenics in Action: Patient Profiling



Back To Top

Isogenics in Action: Drug Screening



Back To Top

Isogenics In Action: Combination Screening



Back To Top